Other Stories

Full Video

U.S. FDA authorizes AstraZeneca's preventative COVID-19 antibody treatment, 'Evushield' Updated: 2021-12-09 17:06:20 KST

The U.S. FDA has authorized emergency use of AstraZeneca's preventative COVID-19 antibody treatment.
"Evushield" will be used for certain immunocompromised people aged 12 or older, who may not be able to mount an adequate immune response to COVID-19 vaccination, or those with a history of severe adverse reactions to the vaccine.
According to the FDA, one dose of Evusheld administered as two separate shots, is effective for pre-exposure prevention for up to six months.
The treatment is not an alternative to vaccination, or a treatment for the virus in those who have already tested positive.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.